Olema Pharmaceuticals (OLMA) Set to Post Quarterly Earnings on Monday

Key Points

• Olema Pharmaceuticals is expected to report Q3 2026 results on November 9, with analysts forecasting a loss of $0.60 per share and revenue of $1.25 million. The company previously reported a $0.61 per-share loss, missing estimates by $0.06.
• OLMA shares opened at $7.00, well below their 50-day and 200-day moving averages of $8.84 and $14.17, respectively, and have fallen substantially from the 52-week high of $36.26.
• Despite mixed analyst actions and a recent price-target reduction, coverage remains broadly positive: 11 analysts rate the stock Buy, producing a “Moderate Buy” consensus and an average target price of $40.60. Olema is developing palazestrant, an oral therapy for advanced estrogen receptor-positive breast cancer.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) is expected to announce its Q3 2026 resultson Monday, November 9th. Analysts expect the company to post earnings of ($0.60) per share and revenue of $1.25 million for the quarter. Investors may review the information on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.06). On average, analysts expect Olema Pharmaceuticals to post ($2.43) EPS for the current fiscal year and ($2.72) EPS for the next fiscal year.

Olema Pharmaceuticals Price Performance

Shares of OLMA opened at $7.00 on Monday. The stock's 50-day moving average price is $8.84 and its two-hundred day moving average price is $14.17. The stock has a market cap of $612.50 million, a P/E ratio of -3.30 and a beta of 2.12. Olema Pharmaceuticals has a 1 year low of $6.24 and a 1 year high of $36.26. The company has a current ratio of 8.86, a quick ratio of 8.86 and a debt-to-equity ratio of 0.01.

Analysts Set New Price Targets

OLMA has been the topic of a number of research analyst reports. Wall Street Zen lowered Olema Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday, July 25th. Citigroup cut their target price on shares of Olema Pharmaceuticals to $59.00 and set a "buy" rating for the company in a research note on Tuesday, August 11th. Weiss Ratings upgraded shares of Olema Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, September 21st. Stifel Nicolaus dropped their price target on shares of Olema Pharmaceuticals from $48.00 to $30.00 and set a "buy" rating for the company in a research report on Monday, September 14th. Finally, HC Wainwright dropped their price objective on Olema Pharmaceuticals from $38.00 to $36.00 and set a "buy" rating for the company in a research report on Tuesday, August 11th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Olema Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $40.60.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women's cancers, with an emphasis on hormone receptor-positive breast cancer. The company's research is centered on treatments designed to address cancer biology and resistance mechanisms that can limit the effectiveness of existing endocrine therapies.

Olema's lead product candidate is palazestrant, an oral selective estrogen receptor degrader (SERD) being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.